The IMpassion031 trial, incorporating atezolizumab alongside neoadjuvant chemotherapy, has showcased remarkable long-term outcomes in patients with stage II/III triple-negative breast cancer (TNBC).
With approximately 3 years of follow-up data, the final analysis of this phase 3 trial not only confirms the initial success in enhancing pathologic complete response (pCR) rates but also delves into the realm of event-free survival (EFS), disease-free survival (DFS), and overall survival (OS). Moreover, the exploration of circulating tumor DNA (ctDNA) dynamics presents a promising avenue for prognostic biomarkers in TNBC beyond pCR. The study’s meticulous approach to ctDNA analysis sets it apart, offering a broader perspective on disease monitoring and treatment personalization. These findings underscore the growing significance of immune checkpoint inhibitors like atezolizumab in revolutionizing the landscape of early-stage TNBC treatment.
Read more from targetedonc.com